Anbio Biotechnology (NNNN) vs STAAR Surgical (STAA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
STAAR Surgical (STAA) has outperformed Anbio Biotechnology (NNNN) over the past year, losing 16.3% versus a loss of 83.4%. STAAR Surgical is the larger company by market cap ($1.11 billion vs $200.1 million), about 5.6 times the size. On valuation, Anbio Biotechnology trades at a lower trailing P/E (30.4x vs 277.1x for STAAR Surgical).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | STAA |
|---|---|---|
| Share price | $4.56 | $22.17 |
| Market cap | $200.14M | $1.11B |
| 1-day change | -6.94% | -0.87% |
| YTD return | -83.70% | -3.16% |
| 1-year return | -83.37% | -16.32% |
| 5-year return | — | -80.54% |
| P/E ratio (TTM) | 30.40 | 277.06 |
| Forward P/E | — | 19.94 |
| EPS (TTM) | $0.15 | $0.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.73 | $35.87 |
| 52-week low | $4.56 | $15.59 |
| Distance from 52-week high | -89.81% | -38.21% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +26.33% |
| Average volume | 147.21K | 998.64K |
| Shares outstanding | 43.89M | 50.14M |
| Employees | 27 | 921 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STAAR Surgical is about 5.6 times larger than Anbio Biotechnology by market value ($1.11B vs $200.14M).
- STAA has outperformed NNNN by 67.0 percentage points over the past year.
- STAAR Surgical trades at a higher earnings multiple (277.1x vs 30.4x trailing P/E).
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About STAAR Surgical
STAA stock →STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Health Care · Ophthalmic Goods · 921 employees
NNNN vs STAA FAQ
Which is bigger, Anbio Biotechnology or STAAR Surgical?
STAAR Surgical (STAA) is larger, with a market capitalization of $1.11B compared with $200.14M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, NNNN or STAA?
STAA returned -16.32% over the past 12 months, compared with -83.37% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NNNN or STAA?
NNNN has the lower trailing P/E at 30.4, versus 277.1 for STAA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Anbio Biotechnology and STAAR Surgical in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Anbio Biotechnology and Ophthalmic Goods for STAAR Surgical.